Advertisement
Advertisement
ANVS
Annovis Bio, Inc.
1.75
USDSponsored
-0.02
-1.13%
Jul 31, 15:59 UTC -4
Closed
After-Market
1.74
-0.01
-0.51%
ANVS Earnings Reports
Positive Surprise Ratio
ANVS beat 10 of 22 last estimates.
45%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.46
Implied change from Q1 26 (Revenue/ EPS)
--
/-26.98%
Implied change from Q2 25 (Revenue/ EPS)
--
/+43.75%
Annovis Bio, Inc. earnings per share and revenue
On May 15, 2026, ANVS reported earnings of -0.63 USD per share (EPS) for Q1 26, missing the estimate of -0.40 USD, resulting in a -56.37% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -3.29% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of -0.46 USD, with revenue projected to reach -- USD, implying an decrease of -26.98% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Agios Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.70
Actual
-$1.69
Surprise
+0.66%
Vericel Corporation
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.02
Actual
$0.04
Surprise
+239.37%
Wave Life Sciences Ltd. Ordinary Shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.31
Actual
-$0.34
Surprise
-8.94%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.02
Actual
$0.02
Surprise
-0.50%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.25
Actual
$0.00
Surprise
+100.00%
Castle Biosciences, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.07
Surprise
+83.12%
Myriad Genetics Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.25
Surprise
-323.73%
Bristol-Myers Squibb Co.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.60
Actual
$2.04
Surprise
+27.37%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
FAQ
What were Annovis Bio, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Annovis Bio, Inc. reported EPS of -$0.63, missing estimates by -56.37%, and revenue of $0.00, 0% as expectations.
How did the market react to Annovis Bio, Inc.'s Q1 2026 earnings?
The stock price moved down -3.29%, changed from $2.13 before the earnings release to $2.06 the day after.
When is Annovis Bio, Inc. expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Annovis Bio, Inc.'s next earnings report?
Based on 5
analysts, Annovis Bio, Inc. is expected to report EPS of -$0.46 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement